| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
54,750,000 |
| Market
Cap: |
1.39(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.97 - $70.59 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
314,560 |
336,704 |
539,824 |
622,940 |
| Total Sell Value |
$12,361,991 |
$12,684,415 |
$15,261,267 |
$15,750,975 |
| Total People Sold |
4 |
11 |
11 |
13 |
| Total Sell Transactions |
5 |
14 |
25 |
40 |
| End Date |
2025-09-04 |
2025-06-03 |
2024-12-03 |
2023-12-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gut Robert |
Director |
– • – |
2025-11-06 |
4 |
AS |
$27.22 |
$856,881 |
D/D |
(31,434) |
40,145 |
|
- |
|
| Gut Robert |
Director |
– • – |
2025-11-06 |
4 |
OE |
$4.57 |
$72,389 |
D/D |
15,840 |
71,579 |
|
- |
|
| Kaye Jack |
Director |
– • – |
2025-11-04 |
4 |
AS |
$30.33 |
$1,177,517 |
D/D |
(38,810) |
20,439 |
|
-10% |
|
| Kaye Jack |
Director |
– • – |
2025-11-04 |
4 |
OE |
$5.37 |
$383,535 |
D/D |
38,810 |
38,249 |
|
- |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2025-09-26 |
4 |
AS |
$55.00 |
$825,000 |
D/D |
(15,000) |
217,730 |
|
-49% |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2025-09-26 |
4 |
OE |
$5.37 |
$80,550 |
D/D |
15,000 |
232,730 |
|
- |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2025-09-24 |
4 |
AS |
$40.04 |
$120,120 |
D/D |
(3,000) |
217,730 |
|
-42% |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2025-09-24 |
4 |
OE |
$13.03 |
$39,090 |
D/D |
3,000 |
220,730 |
|
- |
|
| Kapusta Matthew C |
CEO, Managing Director |
• • – |
2025-09-24 |
4 |
AS |
$39.59 |
$9,382,473 |
D/D |
(226,316) |
651,454 |
|
-42% |
|
| Kapusta Matthew C |
CEO, Managing Director |
• • – |
2025-09-24 |
4 |
OE |
$6.22 |
$1,474,909 |
D/D |
226,316 |
877,770 |
|
- |
|
| Abi-Saab Walid |
Chief Medical Officer |
• – – |
2025-06-27 |
4 |
S |
$13.92 |
$20,407 |
D/D |
(1,466) |
150,437 |
|
-120% |
|
| Kaye Jack |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$30,518 |
D/D |
(2,112) |
20,439 |
|
-393% |
|
| Post Leonard E |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$30,518 |
D/D |
(2,112) |
29,937 |
|
-393% |
|
| Gut Robert |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$48,205 |
D/D |
(3,336) |
56,879 |
|
-393% |
|
| Meek David D. |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$30,518 |
D/D |
(2,112) |
34,190 |
|
-393% |
|
| Springhorn Jeremy P. |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$30,518 |
D/D |
(2,112) |
37,694 |
|
-393% |
|
| Jacques Rachelle Suzanne |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$30,518 |
D/D |
(2,112) |
28,346 |
|
-393% |
|
| Balachandran Madhavan |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$30,518 |
D/D |
(2,112) |
37,697 |
|
-393% |
|
| Potts Jeannette |
Chief Legal Officer |
• – – |
2025-06-16 |
4 |
S |
$15.14 |
$70,704 |
D/D |
(4,670) |
115,073 |
|
-293% |
|
| Jacques Rachelle Suzanne |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
30,458 |
|
- |
|
| Post Leonard E |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
32,049 |
|
- |
|
| Springhorn Jeremy P. |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
39,806 |
|
- |
|
| Balachandran Madhavan |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
39,809 |
|
- |
|
| Meek David D. |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
36,302 |
|
- |
|
| Gut Robert |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
60,215 |
|
- |
|
401 Records found
|
|
Page 1 of 17 |
|
|
1.25 (4.7%) 
